Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Global Severe Acne Vulgaris Treatment Market Share, Size, Analysis, Growth, Forecast, Trends: By Drugs: Prescription Medicines, Over-the-Counter Medicines; By Type: Non-Inflammatory Acne, Inflammatory Acne; By Treatment Method; By Age Group; By Distribution Channel; By Treatment Channel; Regional Analysis; Supplier Landscape; 2023-2031
Global Severe Acne Vulgaris Treatment Market Report
The rising prevalence of acne drives the value of the global severe acne vulgaris treatment market. The number of acne cases among people was 742.3 million in 2021. The prevalence of acne vulgaris is likely to grow at a CAGR of 1.73% in the forecast period of 2023-2031. With this growth rate, the number of cases is expected to reach approximately 866 million by 2030.
Introduction
Acne, or acne vulgaris, is a common skin condition that occurs when hair follicles are clogged with excessive production of sebum, dust, and dead skin cells. It is accompanied by acne, blackheads, blackheads, or scars.
Acne is divided into inflammatory acne and non-inflammatory acne. Acne treatments include removing dead skin cells, reducing oil production, and killing bacteria with medications and drugs.
Several studies have confirmed that acne can affect a person's quality of life, self-esteem, and mood. Acne is a chronic inflammatory skin disease with a multifactorial etiology. It is caused by hormonal changes during puberty and is exacerbated by genetics and other factors.
Acne medications include various prescription and over-the-counter medications, such as retinoids, isotretinoin, antibiotics, salicylic acid, benzoyl peroxide, and oral contraceptives.
The side effects of acne treatment vary on the choice and the power of medicine. The most common side effects are dry skin and irritation. The potential side effects of oral medications can be more serious. Antibiotics can upset your stomach and make you feel lightheaded or dizzy.
In addition, oral isotretinoin can cause serious side effects, especially if the patient becomes pregnant while taking it. Serious birth defects have been reported in infants whose mothers took isotretinoin during pregnancy. The drug may increase the risk of depression and suicide and may affect cholesterol levels and liver function. Safety issues related to acne products prevent the growth of global severe acne vulgaris treatment market.
Factors such as increasing prevalence of acne among teenagers and adults, increasing sedentary lifestyle and unhealthy eating habits, and increasing demand for minimally invasive cosmetic treatment procedures have propelled the demand and fuelled the market growth. However, safety concerns related to products used to treat acne are hindering the growth of the severe acne vulgaris treatment market.
According to the global severe acne vulgaris treatment research report, the market can be categorized into the following segments:
Market Breakup by Drugs
- Prescription Medicines
- Over-the-Counter Medicines
Market Breakup by Type
- Non-Inflammatory Acne
- Inflammatory Acne
Market Breakup by Treatment Method
- Systemic Therapy
- Hormonal Therapy
- Oral Contraceptive
- Spironolactone
- Cyproterone Acetate
- Flutamide
- Topical Antibiotics
- Erythromycin
- Clindamycin
- Clarithromycin
- Azithromycin
- Nadifloxacin
- Topical Retinoids
- Adapalene
- Tazarotene
- Tretinoin
- Isotretinoin
- Metretinide
- Retinaldehyde
- Beta-Retinoyl Glucuronide
- Physical Treatment
- Lesion Removal
- Phototherapy
- Topical Combination Therapy
- Chemical Peeling
- Glycolic Acids Peel
- Salicylic Acid Peel
- Pulsed Dye Laser Treatment
- Others
- Chemical Peeling
Market Breakup by Age Group
- 10-17 years
- 18-40 years
- 40-65 years
- 65 and Above
Market Breakup by Distribution Channel
- Derma Clinics
- Pharmacy
- E-Commerce
Market Breakup by Treatment Channel
- Public
- Private
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Increase Prevalence of Acne is Driving the Market Growth
Acne vulgaris is a common skin condition affecting the world population, with the highest prevalence among adolescents. It affects more men than women of all ethnic groups. Acne is the most common skin condition in the United States, affecting approximately 50 million Americans each year, according to the American Academy of Dermatology.
The increasing prevalence and severity of acne is driving the global acne vulgaris treatment market. Acne vulgaris is the most common acne disease with a significant psychological impact on adult female victims. About 80% of teenagers between the ages of 12 and 25 have acne. The indisposition of acne has led researchers to investigate the pathological factors of acne treatments.
Additionally, technological advancements that offer fewer demanding features and proven results can be seen as future market opportunities to drive global severe acne vulgaris treatment market growth.
Increase in Expenditure on Cosmetic Products Driving the Severe Acne Vulgaris Treatment Market
The demand for minimally invasive cosmetic procedures is growing significantly worldwide. Dermatologists prefer to treat skin conditions with topical or minimally invasive procedures over surgical methods. Better informed decision-making, better patient-doctor relationships, and better-documented procedures will lead to increased demand for treatments for facial and skin problems. This has led to the adoption of less painful procedures for combined aesthetic therapy.
In addition, the increase in expenditure on cosmetic products and the increase in awareness of diseases among people are fuelling the growth of the global severe acne vulgaris treatment market.
North America is Dominating the Severe Acne Vulgaris Treatment Market
North America accounted for the largest share of the global market and is expected to maintain its dominance, owing to numerous advancements in acne treatments. However, Asia Pacific is expected to register the highest CAGR during the forecast period due to increased product launches, high demand for acne treatments and rising healthcare costs, and increased awareness of newly developed treatments.
Several factors such as unhealthy lifestyle, diet and smoking, hormonal changes and excessive sebum production have increased the prevalence of acne. Also, dermatological studies show that more people are affected by acne in Western societies, including North America.
The burden of acne is widespread in North America and its prevalence has steadily increased with population growth. This continued expansion highlights dermatology's unmet needs and potential business opportunities to improve the accessibility and delivery of anti-acne medications.
Therapeutic Landscape
According to the expert, the development of acne treatments is currently focused on overcoming inflammation and redesigning the carriers of existing active drugs to increase efficacy and tolerability.
Over the counter (OTC) acne medications often contain benzoyl peroxide, salicylic acid, and sulphur. These medications come in a variety of forms, such as oral and topical formulations. OTC medications are primarily used in the mild acne population. Due to the prevalence of mild acne, there is a high demand for OTC medications. This will help the global severe acne treatment market grow at a rapid pace during the forecast period.
Topical benzoyl peroxide has a bactericidal effect against Cutibacterium acnes, an important component of acne vulgaris. Benzoyl peroxide is converted to benzoic acid when it is absorbed through the skin. About 5% of benzoic acid is absorbed and excreted by the renal system.
The remaining benzoic acid is metabolised by cysteine in the skin, releasing active oxygen in free radicals and causing the oxidation of bacterial proteins. The improvement of acne vulgaris is achieved by reducing lipids, free fatty acids, and P. acnes.
Topical benzoyl peroxide also has a mild sebostatic effect, contributing to its keratolytic activity and effectiveness in the treatment of comedonal acne. Benzoyl peroxide effectively heals skin wounds by promoting the formation of healthy granulation tissue and rapid epithelial growth.
Clinical Trial
In need to get a safer and more efficient treatment for severe acne vulgaris, researchers are modifying and reformulating drugs and are more drawn towards the study of combination treatment with new targeted therapies. Some of these clinical trials in the process are:
BioPharmX is developing a new proprietary topical minocycline gel formulation (BPX-01) for the treatment of acne vulgaris. This product is the company's first candidate for an anhydrous hydrophilic topical delivery system and minocycline is completely dissolved in our formulation. This formulation is currently in clinical development for patients with inflammatory acne vulgaris lesions.
Bausch Health Companies Inc. and dermatology company Ortho Dermatologics reported statistically significant top-line results in a second pivotal Phase 3 clinical trial evaluating the study drug IDP-126, a combination of a retinoid, antibacterial and antibiotic for the treatment of acne vulgaris in patients over 9 years of age.
Dermata Therapeutics DMT310 is a premium filter product developed based on the technology of the Spongilla platform. The unique filter product is derived from the natural source of Spongilla lacustris and contains multiple active ingredients to treat a variety of inflammatory skin conditions in a weekly application. It is currently in development for the treatment of moderate to severe acne, and mild to moderate psoriasis. It is currently being evaluated in Phase II.
The demand for treatment will drive the global severe acne vulgaris treatment market.
Competitive landscape
The report gives an in-depth analysis of the key players involved in the global severe acne vulgaris treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- AbbVie, Inc (Allergen)
- Botanix Pharmaceuticals Ltd.
- Galderma S.A.
- Bausch Health Companies Inc.
- GlaxoSmithKline Plc.
- Johnson & Johnson Services Inc.
- Almirall S.A.
- Hospira, Inc.
- Viatris (Mylan N.V.)
- Sun Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Bayer AG
- Perrigo Company Plc.
- Boston Scientific Corporation (Lumenis)
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drugs |
|
| Breakup by Type |
|
| Breakup by Treatment Method |
|
| Breakup by Age Group |
|
| Breakup by Distribution Channel |
|
| Breakup by Treatment Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global Severe Acne Vulgaris Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Severe Acne Vulgaris Treatment Market
6.1 Global Severe Acne Vulgaris Treatment Market Overview
6.2 Global Severe Acne Vulgaris Treatment Market Analysis
6.2.1 Market Overview
6.2.1.1 Global Severe Acne Vulgaris Treatment Market Historical Value (2016-2022)
6.2.1.2 Global Severe Acne Vulgaris Treatment Market Forecast Value (2023-2031)
6.3 Global Severe Acne Vulgaris Treatment Market by Drugs
6.3.1 Market Overview
6.3.1.1 Prescription Medicines
6.3.1.2 Over-the-Counter Medicines
6.4 Global Severe Acne Vulgaris Treatment Market by Type
6.4.1 Market Overview
6.4.1.1 Non-Inflammatory Acne
6.4.1.2 Inflammatory Acne
6.5 Global Severe Acne Vulgaris Treatment Market by Treatment Method
6.5.1 Market Overview
6.5.1.1 Systemic Therapy
6.5.1.2 Hormonal Therapy
6.5.1.2.1 Oral Contraceptive
6.5.1.2.2 Spironolactone
6.5.1.2.3 Cyproterone Acetate
6.5.1.2.4 Flutamide
6.5.1.3 Topical Antibiotics
6.5.1.3.1 Erythromycin
6.5.1.3.2 Clindamycin
6.5.1.3.3 Clarithromycin
6.5.1.3.4 Azithromycin
6.5.1.3.5 Nadifloxacin
6.5.1.4 Topical Retinoids
6.5.1.4.1 Adapalene
6.5.1.4.2 Tazarotene
6.5.1.4.3 Tretinoin
6.5.1.4.4 Isotretinoin
6.5.1.4.5 Metretinide
6.5.1.4.6 Retinaldehyde
6.5.1.4.7 Beta-Retinoyl Glucuronide
6.5.1.5 Physical Treatment
6.5.1.5.1 Lesion Removal
6.5.1.5.2 Phototherapy
6.5.1.6 Topical Combination Therapy
6.5.1.7 Chemical Peeling
6.5.1.7.1 Glycolic Acids Peel
6.5.1.7.2 Salicylic Acid Peel
6.5.1.8 Pulsed Dye Laser Treatment
6.5.1.9 Others
6.6 Global Severe Acne Vulgaris Treatment Market by Age Group
6.6.1 Market Overview
6.6.1.1 10-17 years
6.6.1.2 18-40 years
6.6.1.3 40-65 years
6.6.1.4 65 and Above
6.7 Global Severe Acne Vulgaris Treatment Market by Distribution Channel
6.7.1 Market Overview
6.7.1.1 Derma Clinics
6.7.1.2 Pharmacy
6.7.1.3 E-Commerce
6.8 Global Severe Acne Vulgaris Treatment Market by Treatment Channel
6.8.1 Public
6.8.2 Private
6.9 Global Severe Acne Vulgaris Treatment Market by Region
6.9.1 Market Overview
6.9.1.1 North America
6.9.1.2 Europe
6.9.1.3 Asia Pacific
6.9.1.4 Latin America
6.9.1.5 Middle East and Africa
6.9.2 North America
6.9.2.1 Historical Trend (2016-2022)
6.9.2.2 Forecast Trend (2023-2031)
6.9.2.3 Break Up by Country
6.9.2.3.1 United States of America
6.9.2.3.2 Canada
6.9.3 Europe
6.9.3.1 Historical Trend (2016-2022)
6.9.3.2 Forecast Trend (2023-2031)
6.9.3.3 Break Up by Country
6.9.3.3.1 United Kingdom
6.9.3.3.2 Germany
6.9.3.3.3 France
6.9.3.3.4 Italy
6.9.3.3.5 Others
6.9.4 Asia Pacific
6.9.4.1 Historical Trend (2016-2022)
6.9.4.2 Forecast Trend (2023-2031)
6.9.4.3 Break Up by Country
6.9.4.3.1 China
6.9.4.3.2 Japan
6.9.4.3.3 India
6.9.4.3.4 ASEAN
6.9.4.3.5 Australia
6.9.4.3.6 Others
6.9.5 Latin America
6.9.5.1 Historical Trend (2016-2022)
6.9.5.2 Forecast Trend (2023-2031)
6.9.5.3 Break Up by Country
6.9.5.3.1 Brazil
6.9.5.3.2 Argentina
6.9.5.3.3 Mexico
6.9.5.3.4 Others
6.9.6 Middle East and Africa
6.9.6.1 Historical Trend (2016-2022)
6.9.6.2 Forecast Trend (2023-2031)
6.9.6.3 Break Up by Country
6.9.6.3.1 Saudi Arabia
6.9.6.3.2 United Arab Emirates
6.9.6.3.3 Nigeria
6.9.6.3.4 South Africa
6.9.6.3.5 Others
7 Current Scenario Evaluation and Regulatory Framework
7.1 Emerging Therapies and Clinical Trials Synopsis
7.2 Patent Landscape
7.2.1 Patent Overview
7.2.1.1 Patent Status and Expiry
7.2.1.2 Timelines from Drug Development to Commercial Launch
7.2.1.3 New Drug Application
7.2.1.3.1 Documentation and Approval Process
7.3 Cost of Treatment
7.4 Regulatory Framework
7.4.1 Regulatory Overview
7.4.1.1 US FDA
7.4.1.2 EU EMA
7.4.1.3 INDIA CDSCO
7.4.1.4 JAPAN PMDA
7.4.1.5 Others
8 Challenges and Unmet Need
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Global Severe Acne Vulgaris Treatment Market Dynamics
9.1 Market Drivers and Constraints
9.2 SWOT Analysis
9.3 Porter’s Five Forces Model
9.4 Key Demand Indicators
9.5 Key Price Indicators
9.6 Industry Events, Initiatives and Trends
9.7 Value Chain Analysis
10 Supplier Landscape
10.1 AbbVie, Inc (Allergen)
10.1.1 Company Overview
10.1.2 Product Portfolio
10.1.3 Demographic Reach and Achievements
10.1.4 Mergers and Acquisitions
10.1.5 Certifications
10.2 Botanix Pharmaceuticals Ltd.
10.2.1 Company Overview
10.2.2 Product Portfolio
10.2.3 Demographic Reach and Achievements
10.2.4 Mergers and Acquisitions
10.2.5 Certifications
10.3 Galderma S.A.
10.3.1 Company Overview
10.3.2 Product Portfolio
10.3.3 Demographic Reach and Achievements
10.3.4 Mergers and Acquisitions
10.3.5 Certifications
10.4 Bausch Health Companies Inc.
10.4.1 Company Overview
10.4.2 Product Portfolio
10.4.3 Demographic Reach and Achievements
10.4.4 Mergers and Acquisitions
10.4.5 Certifications
10.5 GlaxoSmithKline Plc.
10.5.1 Company Overview
10.5.2 Product Portfolio
10.5.3 Demographic Reach and Achievements
10.5.4 Mergers and Acquisitions
10.5.5 Certifications
10.6 Johnson & Johnson Services Inc.
10.6.1 Company Overview
10.6.2 Product Portfolio
10.6.3 Demographic Reach and Achievements
10.6.4 Mergers and Acquisitions
10.6.5 Certifications
10.7 Almirall S.A.
10.7.1 Company Overview
10.7.2 Product Portfolio
10.7.3 Demographic Reach and Achievements
10.7.4 Mergers and Acquisitions
10.7.5 Certifications
10.8 Hospira, Inc.
10.8.1 Company Overview
10.8.2 Product Portfolio
10.8.3 Demographic Reach and Achievements
10.8.4 Mergers and Acquisitions
10.8.5 Certifications
10.9 Viatris (Mylan N.V.)
10.9.1 Company Overview
10.9.2 Product Portfolio
10.9.3 Demographic Reach and Achievements
10.9.4 Mergers and Acquisitions
10.9.5 Certifications
10.10 Sun Pharmaceutical Industries Ltd.
10.10.1 Company Overview
10.10.2 Product Portfolio
10.10.3 Demographic Reach and Achievements
10.10.4 Mergers and Acquisitions
10.10.5 Certifications
10.11 Pfizer Inc.
10.11.1 Company Overview
10.11.2 Product Portfolio
10.11.3 Demographic Reach and Achievements
10.11.4 Mergers and Acquisitions
10.11.5 Certifications
10.12 Teva Pharmaceutical Industries Ltd.
10.12.1 Company Overview
10.12.2 Product Portfolio
10.12.3 Demographic Reach and Achievements
10.12.4 Mergers and Acquisitions
10.12.5 Certifications
10.13 Bayer AG
10.13.1 Company Overview
10.13.2 Product Portfolio
10.13.3 Demographic Reach and Achievements
10.13.4 Mergers and Acquisitions
10.13.5 Certifications
10.14 Perrigo Company Plc.
10.14.1 Company Overview
10.14.2 Product Portfolio
10.14.3 Demographic Reach and Achievements
10.14.4 Mergers and Acquisitions
10.14.5 Certifications
10.15 Boston Scientific Corporation (Lumenis)
10.15.1 Company Overview
10.15.2 Product Portfolio
10.15.3 Demographic Reach and Achievements
10.15.4 Mergers and Acquisitions
10.15.5 Certifications
11 Recommendations and Discussion
12 Global Severe Acne Vulgaris Treatment Drugs Distribution Model (Additional Insight)
12.1 Overview
12.2 Potential Distributors
12.3 Key Parameters for Distribution Partner Assessment
13 Payment Methods (Additional Insight)
13.1 Government Funded
13.2 Private Insurance
13.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
In 2021, the prevalence of acne vulgaris reached 742.3 million people worldwide.
The prevalence rate of severe acne vulgaris is likely to grow at a CAGR of 1.73% during the forecast period of 2023-2031. The prevalence of acne vulgaris is likely to reach 866 million by 2030.
The major regions in the industry are North America, Latin America, the Middle East, Africa, Europe, and the Asia Pacific, with North America accounting for the largest share of the market.
Asia Pacific region has the highest growth rate in the severe acne vulgaris treatment market.
AbbVie, Inc (Allergen), Botanix Pharmaceuticals Ltd., Galderma S.A., Bausch Health Companies Inc., GlaxoSmithKline Plc., Johnson & Johnson Services Inc., Almirall S.AHospira, Inc., Viatris (Mylan N.V.), Sun Pharmaceutical Industries Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bayer AG, Perrigo Company Plc., and Boston Scientific Corporation (Lumenis). are among the key players in the market.
Based on the drugs, the global severe acne vulgaris treatment market can be segmented into prescription medicines and over-the-counter medicines.
Based on the types, the market can be segmented into inflammatory acne and non-inflammatory acne.
Based on the distribution channel, the market can be segmented into retail store, pharmacy and drug store, and e-commerce.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$2499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$4999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$6499-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$7999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER